Best of the Week: November 21 – November 27, 2025 | Cannabis Science and Technology

Let’s dive into the top stories shaping the conversation this week. Summaries of each article are listed below.

In the cannabis industry, the day before Thanksgiving is referred as the biggest sales day of the year. The holiday event is called “Green Wednesday” and can better be known as the “Black Friday” for cannabis.

To celebrate, Cannabis Science and Technology put the spotlight on cannabis by compiling green-related content, new and old. From product manufacturing of edibles, topicals, and pre-rolls to other cannabis science, the cannabis plant is a fascinating subject that Cannabis Science and Technology is dedicated to covering closely.

The verdict is in on hemp in Ohio. After going through the House and Senate in the Buckeye State, Senate Bill 56 (SB 56) was sent to a legislative conference committee where members voted to approve, as well as advance a “negotiated” version of the bill. The new version brings new updates to the voter-approved adult-use cannabis legalization legislation.

Senate Bill 56 would limit the sale of some hemp-derived products so that they can only be purchased from state-licensed dispensaries, establish a path for individuals who are interested in expunging prior cannabis-related convictions, specify that adults can consume cannabis legally within their private property, as well as redirect a portion of tax revenues stemming from cannabis transactions that would go to individual municipalities that license cannabis retailers.

On November 24, 2025, the US Hemp Roundtable issued a press release regarding the action points needed for the hemp industry following the passage of the FY26 Agriculture Appropriations Bill.

“Our first priority is to secure an additional one-year moratorium on the effective date of the ban,” the press release states. “We’ve seen a strong public backlash, with many more Members of Congress raising their voices in favor of regulation, not prohibition. This additional one-year period would allow for the appropriate level of transparency and scrutiny needed to reach a responsible resolution.”

The November installment of the monthly Healer webinars, hosted by Dustin Sulak, DO, covered multiple published studies on cannabis for various conditions including diabetic neuropathy, chronic back pain, and opioid induced persistent apnea. The webinar also covered recent research in cannabinoids and Alzheimer’s disease symptoms.

Researchers in Israel explored cannabis plant terpenes, discovering that in a dose-dependent manner, that cannabis plant terpenes were activating endogenous cannabinoid receptors. Preclinical data was published in the journal, Biochemical Pharmacology. Study organizers evaluated the modularity ability of 16 terpenes from the cannabis plant which included α-pinene, β-pinene, limonene, myrcene, ocimene, sabinene, terpinolene, borneol, eucalyptol, geraniol, linalool, terpineol, β-caryophyllene, humulene, bisabolol, and nerolidol.

“This study provides evidence suggesting that multiple cannabis-derived terpenes, when tested in the absence of cannabinoids, act as partial agonists at CB1R and CB2R, with significant variability in apparent potency, efficacy, and receptor selectivity,” the study’s authors explained. “Collectively, these findings suggest a pharmacological basis for incorporating specific terpenes into ECS-focused product design and warrant further research into their tissue-specific activity, and synergistic potential when used in combination with cannabinoids or other therapeutic agents.”